Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: A case-control study

Haematologica

Volumn 96, Issue 2, 2011, Pages 337-341

  Even, Caroline ^a   Bastuji Garin, Sylvie ^a,b,c   Hicheri, Yosr ^a,d   Pautas, Cécile ^a   Botterel, Francoise ^b,d,e   Maury, Sébastien ^a,d   Cabanne, Ludovic ^a   Bretagne, Stéphane ^b,d,e   Cordonnier, Catherine ^a,d,e  

^a HENRI MONDOR HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^d FACULTÉ DE MÉDECINE   (France)

^e UNIVERSITÉ PARIS EST   (France)

Author keywords

Chemotherapy; Infection; Invasive fungal disease; Leukemia; Survival

Indexed keywords

ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; ASPERGILLOSIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CANDIDIASIS; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EVENT FREE SURVIVAL; FEMALE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MALE; OVERALL SURVIVAL; PROGNOSIS; SYSTEMIC MYCOSIS; THERAPY DELAY; ZYGOMYCOSIS;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYCOSES; OPPORTUNISTIC INFECTIONS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVAL RATE; YOUNG ADULT;

EID: 79551617211     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.030825     Document Type: Article

References (24)

1. Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G, et al. invasive aspergillosis in patients with acute myeloid leukemia: SEIFEM-2008 registry study. Haematologica. 2010;95(4):644-50.
2. Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Ame S, Fohrer C, et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis. 2008;47(9):1176-84.
3. Cornely O, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44(10):1289-97.
4. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408-15.
5. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised doubleblind trial. Lancet. 2007;369(9572):1519-27.
6. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45(7):883-93.
7. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356 (24):2472-82.
8. Slobbe L, Polinder S, Doorduijn JK, Lugtenburg PJ, el Barzouhi A, Steyerberg EW, et al. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis. 2008;47(12):1507-12.
9. Sipsas NV, Kontoyiannis DP. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin Infect Dis. 2006;42(11):1584-91.
10. Cordonnier C, Rovira M, Maertens J, Olavarria E, Faucher C, Bilger K, et al. Voriconazole for Secondary Prophylaxis of Invasive Fungal Infection in Allogeneic Stem Cell Transplant Recipients: Results of the VOSIFI Study. Haematologica. 2010;95 (10):1762-8.
11. Maertens J, Marchetti O, Herbrecht R, Cornely OA, Flückiger U, Frere P, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: Summary of the ECIL3 - 2009 Update. Bone Marrow Transplant, 2010.2010 Jul 26. [Epub ahead of print].
12. Walsh TJ, Anaissie EJ, Dennin DW, Herbrecht R, Kontoyaiannis DP, Marr K, et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46(3):327-60.
13. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996; 87(5):1710-7.
14. Buchner T, Hiddemann W, Berdel W, Wormann B, Loffler H, Schoch C, et al. Remission induction therapy: the more intensive the better? Cancer Chemother Pharmacol. 2001;48 (Suppl 1):S41-4.
15. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34(1):7-14.
16. Ades L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French- Belgian-Swiss and PETHEMA results. Blood. 2008;111(3):1078-84.
17. Gardin C, Turlure P, Fagot T, Thomas X, Terre C, Contentin N, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood. 2007;109(12):5129-35.
18. Thomas X, Raffoux E, Botton S, Pautas C, Arnaud P, de Revel T, et al. Effect of priming with granulocyte-macrophage colonystimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia. 2007;21(3):453-61.
19. Dombret H, Gabert J, Boiron J, Rigal- Huguet F, Blaise D, Thomas X, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia - results of the prospective multicenter LALA-94 trial. Blood. 2002;100(7):2357-66.
20. Thomas X, Boiron J, Hughet F, Dombret H, Bradstock K, Vey N, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: Analysis of the LALA-94 trial. J Clin Oncol. 2004;22(20):4075-86.
21. Baddley JW, Andes DR, Marr KA, Kontoyiannis DP, Alexander BD, Kauffman CA, et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis. 2010;50 (1):1559-67.
22. Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A, et al. Impact of the intensity of the pretransplant conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2006;108(9):2928-36.
23. Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, et al. Empirical versus pre-emptive antifungal strategy in high-risk febrile neutropenic patients: A prospective randomized study. Clin Infect Dis. 2009;48 (8):1042-51.
24. Cornely OA, Maertens J, Winston DJ, Perfect JR, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. Fluconazole or Itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348-59.